Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel
- PMID: 19699770
- DOI: 10.1016/j.jconrel.2009.08.013
Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel
Abstract
Background: Targeting of a specific subset of cells is mandatory for the successful application of siRNA mediated silencing in anticancer therapy. A recent theory suggests that colon cancer is sustained by a small subpopulation of cells, termed cancer stem cells (CSCs). These cells are characterized by their innate drug resistance properties, which is one of the key factors of chemotherapy failure. The goal of this study was to assess whether a novel siRNA delivery carrier, with an appropriate siRNA, targeted to CD133+ cells has the potential to improve the efficacy of conventional chemotherapy.
Methods: In this study, a novel synthetic siRNA carrier platform was designed and synthesized. This carrier was composed of a cationic oligomer (PEI(1200)), a hydrophilic polymer (polyethylene glycol) and a biodegradable lipid-based crosslinking moiety. Libraries of polymers were synthesized by varying their lipid composition. Their transfection efficacy was evaluated in vitro using CHOK1 cells. The polymer was characterized using molecular weight, particle encapsulation assay, particle size and surface charge analysis.
Results: It was demonstrated that the lipid composition in the polymer plays a critical role in transfection. Optimizing the physicochemical properties of the polymers is crucial in achieving favorable knockdown. Lipid nano complex with composition PEI-Lipid(1:16) was the optimum ratio for gene silencing. Additionally, silencing of multidrug resistance gene (MDR1) and treatment with paclitaxel play a synergistic role in increasing the efficacy as compared to the drug alone.
Conclusions: In the present study a novel siRNA delivery carrier system with an MDR1-targeting siRNA (siMDR1) effectively reduced the expression of MDR1 in human colon CSCs (CD133+ enriched cell population), resulting in significantly increasing the chemosensitivity to paclitaxel.
Similar articles
-
Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.Pharm Res. 2015 Jun;32(6):2097-109. doi: 10.1007/s11095-014-1602-1. Epub 2014 Dec 17. Pharm Res. 2015. PMID: 25515492 Free PMC article.
-
Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers.Biomaterials. 2010 Mar;31(8):2408-16. doi: 10.1016/j.biomaterials.2009.11.077. Epub 2009 Dec 5. Biomaterials. 2010. PMID: 19963269
-
Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.J Control Release. 2015 Oct 28;216:103-10. doi: 10.1016/j.jconrel.2015.08.012. Epub 2015 Aug 10. J Control Release. 2015. PMID: 26272765 Free PMC article.
-
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43. doi: 10.1016/j.ejpb.2013.07.002. Epub 2013 Jul 17. Eur J Pharm Biopharm. 2013. PMID: 23872180 Review.
-
[Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid].Yakugaku Zasshi. 2012;132(12):1355-63. doi: 10.1248/yakushi.12-00234-2. Yakugaku Zasshi. 2012. PMID: 23208041 Review. Japanese.
Cited by
-
Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective.Pharmaceutics. 2021 Dec 8;13(12):2116. doi: 10.3390/pharmaceutics13122116. Pharmaceutics. 2021. PMID: 34959397 Free PMC article. Review.
-
Cancer stem cells in breast cancer.Cancers (Basel). 2011 Mar 15;3(1):1311-28. doi: 10.3390/cancers3011311. Cancers (Basel). 2011. PMID: 24212663 Free PMC article.
-
Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.Expert Opin Drug Deliv. 2017 Jan;14(1):65-73. doi: 10.1080/17425247.2016.1205583. Epub 2016 Jul 6. Expert Opin Drug Deliv. 2017. PMID: 27337289 Free PMC article. Review.
-
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery.Biomaterials. 2013 Jan;34(4):1289-301. doi: 10.1016/j.biomaterials.2012.10.024. Epub 2012 Nov 5. Biomaterials. 2013. PMID: 23137395 Free PMC article.
-
Crossroad between the Heat Shock Protein and Inflammation Pathway in Acquiring Drug Resistance: A Possible Target for Future Cancer Therapeutics.Biomedicines. 2023 Sep 26;11(10):2639. doi: 10.3390/biomedicines11102639. Biomedicines. 2023. PMID: 37893013 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials